Introduction
• Disability-adjusted life years (DALYs) and qualityadjusted life years (QALYs) are two measurements commonly used in healthcare evaluations. They both combine measurements of mortality and morbidity into a single numerical unit.
• In order to calculate QALYs, premature death is combined with morbidity by assigning a weight to different states of health. For example, a value of 0 is used to represent death, while a value of 1 represents full health. This value is then multiplied by the duration a person spends in that state of health to provide the total number of QALYs for a health profile.
• DALYs are calculated also by assigning disease weights, however a value of 0 represents full health and a value of 1 represents death; therefore, in general (when not age-weighted), DALYs can be viewed as an inverse QALY ( Figure 1 ).
• Both QALYs and DALYs are also usually discounted, meaning more weight can be given to immediate over distant outcomes, and both measures can account for disease severity. The two measures however are not interchangeable. 1 For example, DALYs incorporate an age-weighting function, which assigns lower weights to the years of the young and elderly, and the origins of disability and quality of life weights differ significantly. 1, 2 • As a result, differences between the DALY and QALY, where disease burden is accounted for, may arise.
Conclusion
While it is clear that the QALY is used mostly for non-communicable diseases, the most appropriate use of the DALY is unclear. As a result of the fact that the DALY uses age-weighting, consideration of average age of disease onset, in addition to whether the disease is communicable or not, is required. Ensuring an appropriate measure is used becomes even more important in countries where a dual burden of disease is observed due to higher variations in average age of disease onset. Figure 4 ).
• From the database, the leading causes of disease burden were identified as cerebrovascular disease (7.7%) and HIV (12.0%) in China and Thailand, respectively ( Figure 5 ).
Overall burden of disease in terms of non-communicable and communicable diseases in China and Thailand. 
Discussion
• The results from the review of trials identified in the PubMed search suggest that the QALY was the preferred measure for non-communicable diseases in China and Thailand. While the DALY is used equally in communicable and non-communicable diseases in China, it is used predominantly for non-communicable diseases in Thailand. Thus, while the most appropriate use of the QALY may be clear, it is possible that the choice to use the DALY to assess disease burden may need to take into account additional factors aside from the communicability of a disease.
• The DALY uses age-weighting, giving lower weights to years of the young and the elderly. In contrast to this, one QALY always has the same value, regardless of the age at which it is lived.
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The choice to use the QALY or the DALY therefore may need to be made on the basis of the typical age of disease onset, bearing in mind the differences in age of onset of communicable and non-communicable diseases, and differences even within the same disease. Non-communicable diseases, which have a relatively higher burden in the elderly population, generally are assigned higher weights than communicable diseases, which are of most importance in young populations. 1 For example, a developmental disability due to malnutrition, primarily affecting children, has a disease weight of only 0.024, while unipolar major depression, which is a typical adult condition, has a weight of 0.600. 4 Further complexities arise due to the fact that age-weighting has been shown to increase the number of QALYs gained over the number of DALYs saved when a disease starts in the very early years of life and is of short duration. When a disease starts in later years, up to young adulthood, DALYs saved exceed QALYs gained, sometimes by a relatively large margin. Finally, when the disease starts in late adulthood and in older ages, QALYs gained will again exceed DALYs saved.
• From the WHO database, a dual burden of disease was observed in China and Thailand in terms of noncommunicable and communicable diseases; arising potentially from the adoption of habits associated more with developed countries, such as smoking and poor nutritional intake, but without the advancement in healthcare required to reduce disease burden from communicable diseases. 5 In countries like Thailand that face a dual burden of disease in which disease onset varies, careful consideration of this factor is required to ensure the most appropriate measure is used.
• Limitations of this research include the potential for underlying selection bias in publications in this field. Due to the nature of non-communicable diseases, ie. that they generally require expensive treatment, are widespread and are often more longer term than communicable diseases, there may be a tendency to use QALYs preferentially in economic assessments; thereby leading to a higher number of publications reporting QALYs for this reason alone. A further limitation to this work is the small number of trials conducted specifically in Thailand. This prevents a firm conclusion being made on the preference for using DALYs to report noncommunicable and communicable diseases. A more extensive systematic search is therefore required. 
Objectives
• The objective of this study was to assess the use of DALYs and QALYs in trials taking place in China and Thailand and to review the relationship with disease burden. 
Results
The use of QALYs and DALYs in trials conducted in China and Thailand
• 120 studies were included for China, of which 82 reported QALYs and 38 reported DALYs. 43 studies were included for Thailand (QALYs: 36; DALYs: 7) (Figure 2 ).
• Of trials reporting QALYs, 75.6% of Chinese and 80.6% of Thai trials focussed on non-communicable disease, and 24.4% and 19.4% of trials reported on communicable disease, respectively (Figure 3) . The most commonly investigated disease area was oncology.
• Of trials reporting DALYs, 44.7% of Chinese and 16.7% of Thai trials focussed on non-communicable diseases, and 55.3% and 83.3% on communicable diseases ( Figure  3) . The most commonly investigated diseases were diarrhoeal disease, hepatitis and HIV/AIDS.
